Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2020

Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002

20200908 Transgene TG6002 Phase 1 EN

Published 8 September 2020
Categorized as -others, 2020, Invir.IO, Press release, TG6002

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

Jérémy Béguin, et al.Molecular Therapy Oncolytics, September 2020 – Read the articlePublication

Published 2 September 2020
Categorized as 2020, Publication, TG6002

Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs

Jérémy Béguin, et al.BMC Vet Res., August 25 2020 – Read the articlePublication

Published 25 August 2020
Categorized as -others, 2020, Publication, TG6002

Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals

20200804 Transgene – Partial sale Tasly Shares EN

Published 4 August 2020
Categorized as 2020, Press release

Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers

CP TG4001+avelumab EN – Vdef-

Published 22 July 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare

20200709 PR Hypertrust Transgene EN

Published 9 July 2020
Categorized as 2020, Myvac, Press release, TG4050

Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine

Poster EUROoCS H. Le et al. EUROoCS 2020 Download the poster here Poster Presentation

Published 8 July 2020
Categorized as -others, 2020, Publication

Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine

Poster EUROoCS H. Le et al. EUROoCS 2020 Download the poster here Poster Presentation

Published 8 July 2020
Categorized as 2020, BT-001, Publication

Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects

AACR2020 6010 J. Foloppe et al. AACR 2020 Download the poster here Poster Presentation

Published 22 June 2020
Categorized as 2020, Invir.IO, Publication

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironmentAACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster here Poster Presentation

Published 22 June 2020
Categorized as 2020, BT-001, Publication

Posts pagination

Newer posts Page 1 … Page 3 … Page 5 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu